Background – B·R·A·H·M·S MR-proADM

Adrenomedullin is the key

Adrenomedullin, a 52 amino acid peptide, is a member of the calcitonin peptide family1 and is widely expressed in many tissues and organs. It has been shown to have a variety of physiological functions, including immune-modulating, direct bactericidal, diuretic and potent vasodilatory activity1-5, and in healthy conditions, circulates at low picomolar concentrations6.

However, plasma levels are significantly up-regulated in many diseased states, such as hypertension7, renal failure7, lower respiratory diseases8 and septic shock9, in proportion to disease severity7, 10-13. This allows clinicians to determine the patients most at risk of developing complications upon their admission to the ED or ICU, in order to rapidly triage and administer the most effective treatment, in the shortest space of time.



Our solution: MR-proADM
Fast, stable and independent

MR-proADM is a novel biomarker which provides more precise patient risk management and greater confidence in treatment site assignment. Used in a variety of indications, it can enhance routine clinical investigation and treatment, and provide an economical alternative to many current risk assessment scores.


High correlation with increasing severity of disease, and accurate short- to long-term prognostic prediction capability in the ED and ICU


Use in the Emergency Department (ED)

Rapid triaging and risk assessment of patients on admission and throughout the ED can:

  • Decrease time to treatment
  • Increase out-patient treatment
  • Reduce length of stay


Use in the Intensive Care Unit (ICU)

Immediate risk assessment and outcome prognosis in the ICU can:

  • Maximize patient safety
  • Guide most appropriate treatment
  • Provide early warning of additional complication


Optimization of risk assessment and patient management using MR-proADM. Levels are not influenced by food or water intake; No significant gender related differences; Stability of up to 72 hours in EDTA plasma at room temperature and over four freeze / thaw cycles; Well documented for clinical use; Rapidly available to aid timely clinical decision-making using the KRYPTOR™ platform* * assay incubation time 29 mins and small sample volume (26 μL in EDTA plasma)

thermo scientific applied biosystems invitrogen fisher scientific unity lab service